138 related articles for article (PubMed ID: 21893477)
1. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
Friedrich C; Glund S; Lionetti D; Kissling CJ; Righetti J; Patel S; Graefe-Mody U; Retlich S; Woerle HJ
Br J Clin Pharmacol; 2013 Sep; 76(3):445-54. PubMed ID: 23331248
[TBL] [Abstract][Full Text] [Related]
2. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
Eurich DT; Simpson S; Senthilselvan A; Asche CV; Sandhu-Minhas JK; McAlister FA
BMJ; 2013 Apr; 346():f2267. PubMed ID: 23618722
[TBL] [Abstract][Full Text] [Related]
3. Linagliptin: from bench to bedside.
Doupis J
Drug Des Devel Ther; 2014; 8():431-46. PubMed ID: 24851042
[TBL] [Abstract][Full Text] [Related]
4. A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.
Eligar VS; Bain SC
Drug Des Devel Ther; 2013; 7():893-903. PubMed ID: 24039399
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors.
Tasnim J; Hashim NM; Han HC
Cell Biochem Funct; 2024 Mar; 42(2):e3967. PubMed ID: 38480622
[TBL] [Abstract][Full Text] [Related]
6. Choosing a gliptin.
Gupta V; Kalra S
Indian J Endocrinol Metab; 2011 Oct; 15(4):298-308. PubMed ID: 22029001
[TBL] [Abstract][Full Text] [Related]
7. Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins.
Alade AA; Ahmed SA; Mujwar S; Kikiowo B; Akinnusi PA; Olubode SO; Olufemi OM; Ohilebo AA
J Biomol Struct Dyn; 2024 May; 42(8):4029-4047. PubMed ID: 37261796
[TBL] [Abstract][Full Text] [Related]
8. Computational Screening for the Dipeptidyl Peptidase-IV Inhibitory Peptides from Putative Hemp Seed Hydrolyzed Peptidome as a Potential Antidiabetic Agent.
Thongtak A; Yutisayanuwat K; Harnkit N; Noikaew T; Chumnanpuen P
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891918
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Silva Júnior WS; Godoy-Matos AF; Kraemer-Aguiar LG
Biomed Res Int; 2015; 2015():816164. PubMed ID: 26146634
[TBL] [Abstract][Full Text] [Related]
10. Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM).
Mora-Rodríguez JM; Sánchez BG; Bort A; Díaz-Yuste A; Ballester-González R; Arrieta F; Sebastián-Martín A; Díaz-Laviada I
Life Sci; 2024 Jan; 336():122292. PubMed ID: 38030058
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors.
Űrgeová A; Javorský M; Klimčáková L; Židzik J; Šalagovič J; Hubáček JA; Doubravová P; Gotthardová I; Kvapil M; Pelikánová T; Tkáč I; Yaluri AS
Pharmacogenomics; 2020 Apr; 21(5):317-323. PubMed ID: 32308134
[No Abstract] [Full Text] [Related]
12. Linagliptin possibly enhances the efficacy of allosteric xanthine oxidase inhibitors.
Tanemoto M; Kasai T; Iida Y
Int Urol Nephrol; 2024 Jan; 56(1):355-356. PubMed ID: 37155141
[No Abstract] [Full Text] [Related]
13. Comparative Binding Study of Gliptins to Bacterial DPP4-like Enzymes for the Treatment of Type 2 Diabetes Mellitus (T2DM).
Carpio LE; Olivares M; Benítez-Paez A; Serrano-Candelas E; Barigye SJ; Sanz Y; Gozalbes R
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891933
[TBL] [Abstract][Full Text] [Related]
14. Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.
Fleming FF; Yao L; Ravikumar PC; Funk L; Shook BC
J Med Chem; 2010 Nov; 53(22):7902-17. PubMed ID: 20804202
[No Abstract] [Full Text] [Related]
15. Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19.
Carrasco-Sánchez FJ; Carretero-Anibarro E; Gargallo MÁ; Gómez-Huelgas R; Merino-Torres JF; Orozco-Beltrán D; Pines Corrales PJ; Ruiz Quintero MA
Endocrinol Diabetes Nutr (Engl Ed); 2022 Mar; 69(3):209-218. PubMed ID: 35353681
[TBL] [Abstract][Full Text] [Related]
16. [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Jermendy G
Orv Hetil; 2011 Sep; 152(37):1471-6. PubMed ID: 21893477
[TBL] [Abstract][Full Text] [Related]
17. [Incretin-based therapy for treating patients with type 2 diabetes].
Jermendy G
Orv Hetil; 2011 Nov; 152(48):1931-40. PubMed ID: 22071295
[TBL] [Abstract][Full Text] [Related]
18. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
